Bukola Afeni
Bangladesh is ready to partner with NAFDAC to supercharge the pharmaceutical sector, while unlocking massive trade potential, and fortify drug and vaccine security for both nations.
This development is spotlighting Nigeria as a powerhouse partner with Bangladesh’s 180 million-strong population opening doors to blockbuster opportunities.
The High Commissioner of Bangladesh to Nigeria, His Excellency Mr. Miah Md. Kabir, made the disclosure during a courtesy visit to NAFDAC’s Director-General, Prof. Mojisola Christianah Adeyeye, at the agency’s bustling headquarters in Abuja.
The high-stakes meeting zeroed in on mutual wins, ramping up trade volumes, swapping cutting-edge tech, and building ironclad safeguards for medicines and vaccines.
With Nigeria’s market muscle and Bangladesh’s pharma prowess, this is a game-changer for affordable, and secure health solutions across Africa and beyond.
The Director-General of NAFDAC, Prof. Mojisola Adeyeye, reaffirmed the Agency’s commitment to ensuring the availability of safe, high-quality, and efficacious medicines in Nigeria.
She noted that the Nigerian pharmaceutical sector has witnessed significant growth over the years, largely due to NAFDAC’s stringent regulatory framework and enforcement mechanisms.
Prof. Adeyeye further stated that, under her leadership over the past eight years, at least two hundred Nigerian pharmaceutical companies have attained international standards.
She added that the Agency will continue to uphold global best practices by ensuring strict compliance with established regulatory requirements across the pharmaceutical industry.
“NAFDAC does not only approve medicines for distribution but we also conduct continuous post-market surveillance to ensure that approved products maintain their quality, with substandard products promptly withdrawn from circulation through enforcement actions.”
She also highlighted that NAFDAC’s attainment of the World Health Organization (WHO) Maturity Level 3 status has significantly boosted investor confidence, attracting international partnerships and investments into Nigeria’s pharmaceutical sector.
Prof. Adeyeye called on the High Commissioner to encourage Bangladeshi investors to establish pharmaceutical manufacturing companies in Nigeria, leveraging the country’s large population and expanding market potential.
She reiterated that Nigeria remains open to investment, particularly in vaccine manufacturing.
She further noted that NAFDAC is hosting a state-of-the-art vaccines and biological laboratory in Lagos, one of the few of its kind in Sub-Saharan Africa,underscoring the country’s readiness to support advanced pharmaceutical production.
